Today our research project together with Elisabeth TweeSteden Hospital in Tilburg starts. We had a short interview with dr. Vriens, the initiator of this project.
What is the goal of this research project?
Chronic postoperative inguinal pain (CPIP) is the main concern after inguinal hernia repair. Most studies use paper and web based questionnaires to investigate this outcome of the so-called Patient Reported Outcome Measures (PROMs). This way of collecting data has several disadvantages, which can be overcome by this innovative application. The Q1.6 application will be used as a means to prospectively collect data in a non-intrusive and non-stressful way. This may provide a more accurate and extensive real-time view of the development and course of CPIP after inguinal hernia surgery. This first research project is designed to test the feasibility of the application and generated data. Once the application is validated as a monitoring instrument, it can replace the paper questionnaires and improve the quality of pain monitoring after inguinal hernia surgery and improve medical research regarding CPIP.
In what way will apps like the Q1.6 app change the field of patient feedback?
Patient feedback is extremely important in investigating the effectiveness of medical interventions. E-health applications like the Q1.6 app give us the opportunity to generate real-time ‘big data’ as never before. This provides many new research opportunities. Besides, physicians can track their patients in real time and complications can be noted in time. The postoperative course of an individual patient can be compared to the postoperative course of the cohort and can be fed back to the patient or placed in a context. Also, costs can be reduced. For example, in case of an uncomplicated postoperative course, the standard postoperative control at the outpatient department can be cancelled.
What do patients think of the Q1.6 app so far?
During the pilot study, all participating patients were extremely enthusiastic about the Q1.6 app. They all used it for 2.5 months or more. They did not mark the Q1.6 app or the way of asking questions as annoying or stressful. The Q1.6 app was preferred above the paper questionnaires and in the future, the patients would like to be monitored more often using a smartphone application.
Our Q1.6 app is currently being used in a Fortune 500 company to gather feedback within teams. We had a short interview with one of the team leaders.
Why did you want to use the app?
The main reason I wanted the app is because of how easy and effectively one can gather feedback. Our response rate has been ~75% to 80% which is pretty amazing and almost impossible to achieve with a regular survey. The other reason is because the app is very appealing for young people, average age in my organization is probably ~26 so it was very easy to ‘sell’ the idea.
What did you think about it afterwards?
The app met and exceeded my expectations! We were able to gather feedback extremely quickly and monitor results lively, which is awesome. The support from the Q team has been outstanding and very fast. The website to review results is super easy to navigate and you can copy-paste the results to share them with the organization.
What was an additional benefit which you did not expect?
The ability to add questions so quickly was extremely beneficial because it gave us the chance to gather input on hot topics that just came up in the organization.
We are are proud to announce that we are selected for the iStart Business Incubation Program of iMinds. In 2015, iStart was granted second place in the European ‘Top University Business Accelerators’ ranking by UBI Global and was ranked fourthbest in the world.
iMinds (formerly IBBT) is a Flemish non-profit organization, founded by the Flemish Government. It was founded as a research institute, with a focus on information & communication technology (ICT) in general, and applications of broadband technology in particular.
We are looking forward to work together with the iStart coaches to accelerate our business.